Weekly Funding Opportunities

[Med Research]

Reminder from NIH regarding ORCID iD registration
NIH encourages everyone from graduate students to senior scientists to register for an ORCID account<https://orcid.org/register> and link it to their eRA Commons personal profile<https://era.nih.gov/erahelp/ppf/default.htm#PPF_Help/8_2_orcid.htm%3FTocPath%3D_____13> (see this eRA video<https://era.nih.gov/files/ORCID-TwitterVideo/index.html> for a quick step-by-step). But for some grant applicants, it’s an absolute must. ORCID iDs are required for PD/PIs on individual fellowship and career development applications submitted for due dates on or after January 25, 2020. NIH eRA systems will check the PD/PI eRA Commons IDs on all submitted fellowship and career development applications. If there isn’t a linked ORCID iD, an error will be generated preventing the application from moving forward to NIH for consideration. For more details, see the full Guide Notice<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-109.html> or the Open Mike blog<https://nexus.od.nih.gov/all/2019/08/05/linking-orcid-identifiers-to-era-profiles-to-streamline-application-processes-and-to-enhance-tracking-of-career-outcomes/> on this topic.

Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-017.html>
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10.

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-018.html>
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10.

Biospecimen Science Technologies for Basic and Clinical Cancer Research
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-019.html>
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10.

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-020.html>
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed.
Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10.

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 / U01 Clinical Trial Optional)
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-023.html>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities.
U01<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-024.html>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.
Due February 21, 2020; May 28, 2020; and September 29, 2020. Med-RA deadline to receive draft documents for February 21, 2020 deadline: February 10.

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-078.html>
The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project’s originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data.
Due February 26, 2020; October 28, 2020; February 26, 2021; October 28, 2021; February 26, 2022; October 28, 2022. Med-RA deadline to receive draft documents for February 26, 2020 deadline: February 13.

Fine-Mapping Genome-Wide Associated Loci to Identify Proximate Causal Mechanisms of Serious Mental Illness (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-100.html>
Genome-wide association studies (GWAS) have identified statistical relationships between tens of thousands of common single nucleotide variants and over a thousand traits. Due to the correlated nature of nearby genetic variants, GWAS implicate regions of the genome and do not necessarily pinpoint the causal variant(s), gene(s) or mechanism(s) underlying the trait association. The purpose of this funding opportunity announcement is to support systematic fine-mapping of genome-wide significant risk loci associated with serious mental illnesses through robust statistical genetic and functional genomic approaches.
Due February 28, 2020. Med-RA deadline to receive draft documents: February 17.

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-074.html>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called “competing revisions”) from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as “assays”) to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as “markers” or “biomarkers”) for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.
Due February 28, 2020; July 10, 2020; October 27, 2020; February 26, 2021; July 13, 2021; October 26, 2021; February 28, 2022; July 11, 2022; and October 28, 2022. Med-RA deadline to receive draft documents for February 28, 2020 deadline: February 17.

Laboratories to Optimize Digital Health (R01 Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-510.html>
NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention’s effectiveness.
Due March 2, 2020 and November 2, 2020. Med-RA deadline to receive draft documents for March 2, 2020 deadline: February 18.

4DN Organization and Function in Human Health and Disease
New Investigator Projects on 4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-006.html>
To support projects from scientists who are in the early stages of establishing an independent research career that apply new or existing tools to monitor and/or manipulate the 4D nucleome (4DN) in the context of human health and disease. Any human disease or biological process relevant to NIH’s mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant time frames may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles.
Due March 2, 2020. Med-RA deadline to receive draft documents: February 18.
4DN Organization and Function in Human Health and Disease (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-005.html>
To support projects that apply new or existing tools to monitor and/or manipulate the 4D nucleome in the context of human health and disease. Any human disease or biological process relevant to NIH’s mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant timeframes may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles.
Due March 2, 2020. Med-RA deadline to receive draft documents: February 18.
4DN Centers for Data Integration, Modeling and Visualization (UM1 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-004.html>
The purpose of this FOA is to solicit applications for research projects to generate reference datasets and to create navigable maps for the study of the spatial and temporal organization of the nucleus, using genomic and imaging data as well as newly developed visualization and integrative analysis tools.
Due March 17, 2020. Med-RA deadline to receive draft documents: March 4.
Real Time Chromatin Dynamics and Function (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-003.html>
To support the development and application of tools that would enable the monitoring in real-time of the dynamic three-dimensional structure of mammalian genomes and provide insight into how organizing components of 4D genome architecture affect biological processes in live cells.
Due March 17, 2020. Med-RA deadline to receive draft documents: March 4.

Transformative Technology Development for the Human BioMolecular Atlas Program (UG3 / UH3 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-001.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues, particularly for characterizing functional modifications, lipids and the extracellular environment. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for 3D mapping the human body with high resolution.
Due March 3, 2020.

Methods and Measurement in Research with Sexual and Gender Minority (SGM) Populations (R21- Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-20-005.html>
The purpose of this initiative is to support research projects to advance the measurement of constructs relevant to health research with sexual and gender minority (SGM) populations.
Due March 3, 2020. Med-RA deadline to receive draft documents: February 19.

Clinical Trials Planning for Symptomatic Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R34 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-012.html>
The emerging science of vascular contributions to cognitive impairment and dementia (VCID) includes a spectrum of cerebrovascular and cardiovascular diagnoses that negatively impact brain health to the point of resulting in or adding to the burden of cognitive impairment, including dementia. The purpose of this initiative is to provide two years of support for planning activities necessary to initiate a Phase III, maximum five-year clinical trial to evaluate efficacy of interventions for patients with symptomatic VCID.  The planning grant mechanism is designed to: 1) Permit early peer review of the rationale for the proposed clinical trial; 2) Permit assessment of the overall design of the proposed trial; 3) Provide support for the development of documents needed for the conduct of the trial, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the trial. The proposed clinical trial should address VCID treatment in a well-defined subset of VCID and utilize validated biomarkers as appropriate. Clinical trial planning activities carried out with awards funded under this RFA may include, but are not limited to, establishment of the research team and collaborations, development of tools for data management and oversight of the trial, designing trial protocols, procedure manuals, and recruitment strategies; collecting feasibility data; and addressing regulatory approvals.
Due March 31, 2020. Med-RA deadline to receive draft documents: March 18.

Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-072.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support the development of novel therapeutics which are directed to intracellular HIV targets. During the HIV life cycle multiple viral associated proteins are expressed in the infected cell. All are critical to support assembly, release and maturation of the virus. Considering each protein has a defined role in the life cycle, therapeutically targeting one or more may be an effective strategy to obtain potent antiviral activity.
Due April 1, 2020. Med-RA deadline to receive draft documents: March 19.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200110/b2ba36e5/attachment.html>